Navigation Links
Actos Bladder Cancer Lawsuits: Next Status Conference in Federal Actos Litigation Scheduled for January 24, 2013, Bernstein Liebhard LLP Reports
Date:1/20/2013

New York, New York (PRWEB) January 20, 2013

Actos bladder cancer lawsuits continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. The next Status Conference in the Actos litigation has been scheduled for Thursday, January 24, 2013 at 10:30 a.m. According to an agenda posted on the Court’s website on January 16th, items to be discussed include the status of federal and state filings, as well as the status of discovery. (In re: Actos Product Liability Litigation, MDL No. 2299).

“We are pleased to see this litigation moving forward, as we continue to hear from Actos users who have been diagnosed with bladder cancer,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The firm is currently offering free lawsuit evaluations to individuals who may have developed bladder cancer due to long-term use of Actos.

Actos Lawsuits
The U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label in June 2011, after a study found that long-term use of the drug increased the risk for bladder cancer. * While Actos is still available in the U.S., the drug has been pulled from the market in Germany and France due to its association with bladder cancer.**

Actos lawsuits pending in the Western District of Louisiana allege that Takeda Pharmaceuticals and other Defendants concealed their knowledge that Actos could increase the risk for bladder cancer, and failed to provide adequate warnings to consumers and the health care community. According to court documents, the first trial in the federal Actos litigation is scheduled to begin on November 2014, followed by the second trial in July 2015.

Since June 2011, a number of additional studies have confirmed the association between long-term use of Actos and bladder cancer. In May 2012, research published in the British Medical Journal concluded that taking Actos for two years can double the risk of developing bladder cancer. *** A second study published in the Canadian Medical Association Journal in July 2012 concluded that patients taking Actos face a 22 percent increased risk of developing bladder cancer. ****

Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.

*fda.gov/drugs/drugsafety/ucm259150.htm
**medpagetoday.com/Endocrinology/Diabetes/26987
***bmj.com/content/344/bmj.e3645
****health.usnews.com/health-news/news/articles/2012/07/03/another-study-links-diabetes-drug-actos-to-bladder-cancer

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

###
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/actos-lawsuits/actos-bladder-cancer/prweb10340351.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. US Drug Watchdog Now Urges Families Mourning The Loss Of A Diabetic User Of The Diabetes Drug Called Actos Who Developed Bladder Cancer To Call The Johnson Law Group
2. US Drug Watchdog Now Urges Loved Ones Of Diabetics Diagnosed with Bladder Cancer To Call The Johnson Law Group If The Loved One Also Used the Diabetes Drug Called Actos
3. US Drug Watchdog Now Urges Families Of Diabetics Diagnosed with Bladder Cancer To Call The Johnson Law Group If They Used the Diabetes Drug Called Actos
4. US Drug Watchdog Now Urges Family Members Mourning The Loss Of A Loved One Who Developed Bladder Cancer After Using The Diabetes Drug Actos To Call The Johnson Law Group
5. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
6. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
7. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
8. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
9. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
10. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
11. New Lawsuit alleges Actos caused Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: